Shanghai Henlius Biotech

This study tests a new drug called HLX79, given together with rituximab, for people with active kidney inflammation (glomerulonephritis) from membranous nephropathy or lupus. About 24 adults will receive either HLX79 or a placebo, plus rituximab, to see if the combination is safe…

This study tests whether adding a new experimental drug (HLX22) to standard treatment can help people with advanced HER2-positive stomach or gastroesophageal junction cancer live longer without their disease getting worse. About 550 adults who have not had prior treatment for the…

This early-phase study tests a new drug called HLX3901 in people with advanced small cell lung cancer or neuroendocrine carcinoma that has not responded to other treatments. The drug is a special antibody designed to help the immune system attack cancer cells. The main goals are …

This study tests a new drug called HLX17 to see if it works like the approved cancer drug Keytruda. It is for people who have had surgery for lung cancer, melanoma, or kidney cancer. The study will compare how the drugs move through the body, their safety, and how well they work.…

This study tests a new drug, HLX43, in people with advanced esophageal cancer that came back or spread after standard treatment. The drug targets a protein on cancer cells to deliver a toxin. About 72 adults will join to see if the drug shrinks tumors and how safe it is.

This study tests whether combining two experimental drugs (HLX22 and HLX87) works better than standard care as the first treatment for people with HER2-positive breast cancer that has returned or spread. About 706 adults with advanced disease will participate. The main goals are …

This study tests a new combination of two drugs (HLX43 and Serplulimab) in people with advanced solid tumors, including lung cancer. The goal is to find the safest dose and see if the treatment can shrink tumors. About 105 adults who have not responded to other treatments will ta…

This study tests a new drug called HLX37 in people with advanced or metastatic solid tumors (cancers that have spread). The drug is a bispecific antibody that targets two proteins (PD-L1 and VEGF) involved in tumor growth. The main goals are to check the drug's safety, find the r…

This study tests a new drug called HLX43 in 70 people with advanced nasopharyngeal cancer that has come back or spread and no longer responds to standard treatments. The drug targets a protein on cancer cells to deliver a toxin directly. The goal is to see if it can shrink tumors…

This study tests a new drug called HLX43 in 60 adults with advanced colorectal cancer that has stopped responding to standard treatments. The drug is designed to target and kill cancer cells while sparing healthy ones. The main goal is to find the best dose and see if it shrinks …

This study tests a new drug called HLX43 in people with advanced stomach or gastroesophageal junction cancer. The drug is designed to target and kill cancer cells while limiting harm to healthy cells. About 60 adults aged 18 to 75 will receive the treatment to see if it shrinks t…

This study tests an experimental drug called HLX43 in people whose head and neck cancer has returned or spread to other parts of the body. The drug works by attaching a cancer-killing agent to an antibody that targets a protein (PD-L1) on tumor cells. About 167 adults aged 18 to …

This study tests a new drug called HLX43 in people with advanced solid tumors that haven't responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 340 adults aged 18 to 75 will take part in this early-phase trial.

This study tests two drugs (HLX43 and serplulimab) given before surgery to people with non-small cell lung cancer. The goal is to see if the combination can shrink or eliminate tumors, making surgery more effective. About 60 adults with stage II-IIIB lung cancer will participate.

This study tests a new drug (HLX10) that helps the immune system fight cancer, combined with standard chemotherapy, in 26 Japanese patients with extensive-stage small cell lung cancer that hasn't been treated before. The main goal is to see how many patients' tumors shrink or dis…

This study compares a new biosimilar drug (HLX13) to the standard drug YERVOY® for people with advanced liver cancer that cannot be removed by surgery. About 246 adults aged 18-65 will receive either the new drug or the standard one. The goal is to see if the new drug works just …

This early-stage study tests a new drug called HLX42 in people with advanced solid tumors, including lung cancer, that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 102 participants will receive the drug to se…

This study tests a new drug called HLX43 in people with advanced cervical or ovarian cancer that came back or spread after standard first treatment. The drug targets a protein on cancer cells to deliver a toxin directly. About 190 adults will receive the drug to see if it shrinks…